{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0938","upperLimit":"0.599","value":"0.387"},{"groupId":"OG001","lowerLimit":"0.918","upperLimit":"16.0","value":"0.992"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants with normal renal function received carfilzomib 20 mg/m² IV on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles.","id":"OG000","title":"Normal Renal Function"},{"description":"Participants with ESRD received carfilzomib 20 mg/m² IV on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles.","id":"OG001","title":"End Stage Renal Disease"}],"paramType":"MEDIAN","populationDescription":"PK evaluable population for cycle 1, day 16. One participant was excluded due to samples taken from the infusion arm, distal to the infusion site. Participants with a coefficient of correlation (R²) \\< 0.8 were excluded.","reportingStatus":"POSTED","timeFrame":"Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.","title":"Terminal Half-life (T½) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1","type":"SECONDARY","unitOfMeasure":"hours"}